Evidence map›Paper›PMID 28154100›Full record

ReviewCirculation research2017

Stroke Caused by Atherosclerosis of the Major Intracranial Arteries.

Chirantan Banerjee, Marc I Chimowitz

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Circulation research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05907629 (Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging), which is not on this map. Cited by 232 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
232citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05907629 recruitingnot on this mapstarted 2024, after this paper: background citation

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

TypeobservationalSponsorYale UniversityRan2024 to 2029Enrolled300ConditionsStroke, Intracranial Atherosclerotic Stenosis (ICAS)ArmsMRI
3 · Its place in the literature

Who cites it

232 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

172 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chirantan BanerjeeFrom the Department of Neurology, Stroke Division, Medical University of South Carolina, Charleston.
Marc I ChimowitzFrom the Department of Neurology, Stroke Division, Medical University of South Carolina, Charleston. mchimow@musc.edu.

Funding

SAMMPRIS (Stenting vs. Aggressive Medical Management for Preventing . . .U01NS058728 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI CHIMOWITZ, MARC IVOR · 2008 to 2011
$20.0M
WARFARIN VS ASPIRIN FOR INTRACRANIAL ARTERIAL STENOSISR01NS036643 · NINDS · EMORY UNIVERSITY · PI CHIMOWITZ, MARC IVOR · 1998 to 2002
$9.1M
NINDS NIH HHS R01 NS036643NINDS NIH HHS U01 NS058728
6 · The paper itself

Abstract

Our goal in this review is to discuss the pathophysiology, diagnosis, and treatment of stroke caused by atherosclerosis of the major intracranial arteries. References for the review were identified by searching PubMed for related studies published from 1955 to June 2016 using search terms intracranial stenosis and intracranial atherosclerosis. Reference sections of published randomized clinical trials and previously published reviews were searched for additional references. Intracranial atherosclerotic disease is a highly prevalent cause of stroke that is associated with a high risk of recurrent stroke. It is more prevalent among blacks, Hispanics, and Asians compared with whites. Diabetes mellitus, hypertension, metabolic syndrome, smoking, hyperlipidemia, and a sedentary lifestyle are the major modifiable risk factors associated with intracranial atherosclerotic disease. Randomized clinical trials comparing aggressive management (dual antiplatelet treatment for 90 days followed by aspirin monotherapy and intensive management of vascular risk factors) with intracranial stenting plus aggressive medical management have shown medical management alone to be safer and more effective for preventing stroke. As such, aggressive medical management has become the standard of care for symptomatic patients with intracranial atherosclerotic disease. Nevertheless, there are subgroups of patients who are still at high risk of stroke despite being treated with aggressive medical management. Future research should aim to establish clinical, serological, and imaging biomarkers to identify high-risk patients, and clinical trials evaluating novel therapies should be focused on these patients.

Indexed as

Clinical Trials as TopicEndovascular ProceduresHumansIntracranial ArteriosclerosisPlatelet Aggregation InhibitorsRisk FactorsStrokePlatelet Aggregation Inhibitorsarteriesaspirindiabetes mellitushypertensionrisk factorsstroke

Identifiers

PMID28154100
PMCPMC5312775

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.